Saxagliptin inib NF-kappaB signaling blockade by Bay

NF-kappaB signaling blockade by Bay 11-7085 during early cardiac morphogenesis induces alterations of the outflow tract in chicken heart

ML277 specifically enhances the fully activated open state of KCNQ1 by modulating VSD-pore coupling

WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib

InChiKey: XGNNCRZDDAJBFU-UHFFFAOYSA-N

58(4):1717-35

Saxagliptin inib NF-kappaB signaling blockade by BaySaxagliptin, also known as BMS 477118, is a new oral hypoglycemic (anti diabetic drug) of the new dipeptidyl peptidase 4 (DPP 4) inhibitor class of drugs. Saxagliptin was approved in 2008 for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose